Moshe Szyf, PhD, is the founder and CEO of HKG epiTherapeutics Ltd. He is a geneticist, a Fellow of the Royal Society of Canada, and the Canadian Academy of Health Science, and previously served as a James McGill Professor Of Pharmacology And Therapeutics at McGill University, where he also held a GlaxoSmithKline-CIHR chair in pharmacology. Szyf’s research in the fields of genetics and early cancer detection spans over three decades. He received his PhD from The Hebrew University and did his postdoctoral fellowship in genetics at Harvard Medical School.
Articles by Moshe Szyf, PhD
|2 min read
Elevating Cancer Diagnostics and Treatment Using Epigenetics
Integrating epigenetic insights into cancer research could help deliver personalized, high-quality, and cost-effective patient carePage 1 of 1
